Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 570
- Registration Number
- NCT00126256
- Locations
- 🇫🇷
Institut Gustave-Roussy, Villejuif, France
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
- Conditions
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00124111
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2013-06-18
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 52
- Registration Number
- NCT00123318
- Locations
- 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Royal North Shore Hospital, Sydney, New South Wales, Australia
🇦🇺Royal Brisbane Hospital, Herston, Queensland, Australia
Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 1060
- Registration Number
- NCT00121992
- Locations
- 🇪🇸
Spanish Breast Cancer Research Group, San Sebastián de los Reyes, Madrid, Spain
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00118261
- Locations
- 🇺🇸
MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸UHHS Chagrin Highlands Medical Center, Cleveland, Ohio, United States
🇺🇸Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 285
- Registration Number
- NCT00117572
- Locations
- 🇭🇷
University Hospital for Tumors Zagreb, Zagreb, Croatia
🇺🇸Joliet Oncology Hematology Associates, Joliet, Illinois, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-06-08
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 15
- Registration Number
- NCT00113399
- Locations
- 🇺🇸
Lynn Regional Cancer Center at Boca Raton Community Hospital - Main Center, Boca Raton, Florida, United States
🇺🇸Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford, Salem, Ohio, United States
🇺🇸AnMed Health Cancer Center, Anderson, South Carolina, United States
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 342
- Registration Number
- NCT00112658
- Locations
- 🇫🇷
Hopitaux Civils de Colmar, Colmar, France
🇫🇷Clinique Saint Vincent, Epernay, France
🇫🇷Centre Hospitalier General, Belfort, France
Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 71
- Registration Number
- NCT00112697
- Locations
- 🇫🇷
Centre Regional Rene Gauducheau, Nantes-Saint Herblain, France
🇫🇷Centre Hospitalier Lyon Sud, Pierre Benite, France
🇫🇷Centre Rene Huguenin, Saint Cloud, France
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-05-26
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT00111761
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.